Atopic DermatitisFeatured ArticlesJDD Highlights

December Issue Article Highlight: Bacteriophages: An Alternative to Combat Antibiotic Resistance?

By December 6, 2022No Comments

Dermatology News

JDD Highlights

Please take some time to review the December 2022 issue of the JDD. As a reminder, last month’s articles are still available to JDD subscribers in our Archive Library.

Read the Article

Bacteriophages: An Alternative to Combat Antibiotic Resistance?

by Monik Gupta BAa, Madison J. Anzelc MDa, Samuel A. Stetkevich MDa, Craig G. Burkhart MPH MDa,b

ABSTRACT

Background: Antibiotic resistance has become one of the largest pitfalls of modern medicine, and this has fueled the search for a safe and effective alternative. Of these alternatives, bacteriophage (phage) therapy has emerged as a potential option since it is capable of destroying pathogenic bacteria, without disrupting commensal bacterial populations. Although numerous studies have shown its efficacy in various conditions such as dysentery, sepsis, and meningitis, very little research has focused on its prospective usage to treat dermatological conditions. This review discusses the emerging phage therapy studies surrounding infections caused by Cutibacterium acnes (C. acnes), Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa), and Klebsiella pneumoniae (K. pneumoniae). Phage therapy shows major potential for future usage in the field of dermatology, yet further research must be performed to assure safety and efficacy in humans.

J Drugs Dermatol. 2022;21(12):1311-1315. doi:10.36849/JDD.6638

Other Articles

You May Also Like

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…
Journal of Drugs in Dermatology JDD About Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

| Featured Articles, Latest News, Psoriasis, The Latest | No Comments
Did you miss this March article? Generalized pustular psoriasis (GPP) is a serious and unpredictable skin condition with limited treatment options. The Effisayil 1 trial evaluated spesolimab, a monoclonal antibody…
Journal of Drugs in Dermatology JDD About Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

| Featured Articles, Latest News, Oncodermatology, The Latest | No Comments
Prioritizing Skincare in Cancer Treatment: A Latin American Initiative Cancer treatments often lead to skin-related side effects that impact quality of life and, in some cases, treatment adherence. The Latin…

Leave a Reply